Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

Hoth Therapeutics Completes HT-001 Formulation Development for Upcoming Cancer Patient Clinical Trial

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

April 12, 2021

Hoth Therapeutics, Inc. is a patient-focused biopharmaceutical company, together with its manufacturing partner, today announced it has successfully completed the formulation for HT-001, a treatment for cancer patients suffering from cutaneous toxicities (skin, nails, scalp) due to EGFR inhibitor therapies.

HT-001 is expected to start its Phase 2a trial in pending approval of the IND submission. The finalization of the HT-001 formulation will allow the company to begin IND-enabling toxicology studies and manufacturing of clinical batches for the planned Phase 2a clinical trial.

The HT-001 formulation was developed in conjunction with Scientific Advisor Board Members, Dr. Jonathan Zippin, Dr. Adam Friedman, and Dr. Mario Lacouture, to ensure patient-focused attributes were key inputs of the formulation development. The HT-001 formulation includes a proprietary excipient blend to promote a protective skin barrier function after application. Preliminary data has shown effective skin protection up to 24hours after application based on a transepidermal water loss test model. In vitro permeation testing using human skin has also shown high Active Pharmaceutical Ingredients (API) permeation and retention after application of the selected HT-001 formulation.

“Working with our manufacturing partner, we have been able to successfully optimize the HT-001 formulation for topical application by patients while ensuring API solubility and stability,” said Dr. Stefanie Johns, Chief Scientific Officer at Hoth.  “We believe this formulation will not only facilitate positive responses in the target areas of toxicity, but also provide the skin protection needed to potentially make patients more comfortable during EGFR inhibitor therapy.”

Hoth Therapeutics will now focus on completing the required regulatory studies for HT-001.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine